<DOC>
	<DOCNO>NCT02562235</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability , pharmacodynamics pharmacokinetics riociguat age- , sex- body-weight-adjusted dos 0.5 mg , 1.0 mg , 1.5 mg , 2.0 mg 2.5 mg TID child ≥6 le 18 year pulmonary arterial hypertension ( PAH ) group 1 . The study consist two phase : titration phase 8 week maintenance phase 16 week .</brief_summary>
	<brief_title>Riociguat Children With Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Children age ≥6 &lt; 18 year Diagnosed PAH : Idiopathic ( IPAH ) Hereditable ( HPAH ) PAH associate ( APAH ) Connective tissue disease Congenital heart disease shunt closure 6 month ago ( open shunt , confirm RHC le 4 month surgery ) Diagnosis PAH confirm right heart catheterization ( RHC ) time prior enrolment ( patient close shunt RHC le 4 month surgery ) Pulmonary arterial hypertension confirm RHC time prior start study , mean pulmonary artery pressure ( PAPmean ) ≥25 mmHg rest , pulmonary capillary wedge pressure ( PCWP ) leave ventricular enddiastolic pressure ( LVEDP ) ≤15 mmHg , pulmonary vascular resistance ( PVR ) &gt; 240 dyn•sec•cm5 ( i.e. , ≥3.0 wood units•m2 ) Patients must standard care PAH medication , allow Endothelin Receptor Antagonists ( ERA ) and/or Prostacyclin Analogues ( PCA ) , least 12 week prior baseline visit . Two group patient include : Prevalent : Patients currently monotherapy need additional treatment ( discretion investigator ) Incident : Treatment naïve patient initiated PAH medication ( allow ERA /or PCA ) riociguat add patinets stable standard care WHO functional class IIII Adolescent females childbearing potential include study pregnancy test negative . Adolescent female childbearing potential must agree use adequate contraception sexually active . 'Adequate contraception ' define combination least 2 effective method birth control , least one physical barrier ( e.g . condom hormonal contraception implant combine oral contraceptive , certain intrauterine device ) . Adequate contraception require signing informed consent form 6 week last study drug administration . Young men must agree use adequate contraception sexually active . Written inform consent provide applicable child assent provide Concomitant use follow medication : phosphodiesterase ( PDE ) 5 inhibitor ( sildenafil , tadalafil , vardenafil ) nonspecific phosphodiesterase ( PDE ) inhibitor ( theophylline , dipyridamole ) , nitrate NO donor ( amyl nitrite ) form Pretreatment NO donor ( e.g . nitrate ) within last 2weeks visit 1 Active state hemoptysis pulmonary hemorrhage , include event manage bronchial artery embolization history bronchial artery embolization massive hemoptysis within 3 month prior screen Systolic blood pressure ( SBP ) 5 mmHg low age , sex heightadapted level 50th SBP percentile ( NHBPEP , 2004 ) History leftsided heart disease , include valvular disease heart failure Pulmonary hypertension relate condition specify inclusion criterion Pulmonary venoocclusive disease Screening aspartate transaminase ( AST ) and/ alanine transaminase ( ALT ) 3 time upper limit normal ( ULN ) Severe restrictive lung disease Severe congenital abnormality lung , thorax , diaphragm Clinically relevant hepatic dysfunction ( especially Child Pugh C ) Renal insufficiency ( estimate glomerular filtration rate &lt; 30 mL/min/1.73m2 e.g . calculate base Schwartz formula , detailed calculation instruction PH associate idiopathic interstitial pneumonia ( PHIIP )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pulmonary arterial hypertension</keyword>
</DOC>